Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 71 clinical trials
211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia

This phase I/II trial studies the side effects and best dose of 211^astatine(At)-BC8-B10 before donor stem cell transplant in treating patients with high-risk acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndrome, or mixed-phenotype acute leukemia. Radioactive substances, such as astatine-211, linked to monoclonal antibodies, such as BC8, can bind to …

myeloproliferative syndromes
sirolimus
hydroxyurea
remission
hla-a
  • 20 views
  • 07 Oct, 2022
  • 1 location
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

This phase Ib trial determines if samples from a patient's cancer can be tested to find combinations of drugs that provide clinical benefit for the kind of cancer the patient has. This study is also being done to understand why cancer drugs can stop working and how different cancers in …

fluorouracil
sirolimus
oxaliplatin
ruxolitinib
hematologic malignancy
  • 2 views
  • 04 Oct, 2022
  • 1 location
IO-202 as Monotherapy and IO-202 Plus Azacitidine in Patients in AML and CMML

To assess safety and tolerability at increasing dose levels of IO-202 as monotherapy and in combination with Azacitidine in successive cohorts of participants with relapsed or refractory AML with monocytic differentiation and CMML in order to estimate the maximum tolerated dose (MTD) or maximum administered dose (MAD) and select the …

tacrolimus
remission
induction chemotherapy
chronic myelomonocytic leukemia
neoadjuvant therapy
  • 0 views
  • 16 May, 2022
  • 9 locations
A Phase 1 Study of SH1573 Capsules in Subjects With Refractory or Relapsed Acute Myelogenous Leukemia

An open label single-arm clinical trial to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of SH1573 in subjects with advanced relapsed, refractory acute myelogenous leukemia that harbor an IDH2 mutation.

  • 0 views
  • 27 Mar, 2021
  • 2 locations
Study of Enasidenib and Venetoclax in IDH2-Mutated Blood Cancers

The purpose of this research study is to see how safe and tolerable, and to find the highest or best dose, of an investigational combination of drugs called enasidenib and venetoclax, in patients with relapsed (the cancer has come back) or refractory (the cancer does not respond or have stopped …

myelodysplastic syndromes
lymphoma
induction chemotherapy
refractory acute myeloid leukemia (aml)
enasidenib
  • 0 views
  • 06 Dec, 2021
  • 2 locations
Tegavivint for the Treatment of Relapsed or Refractory Leukemia

This phase I trial is to find out the best dose and side effects of tegavivint in treating patients with leukemia that has come back (relapsed) or does not response to treatment (refractory). Tegavivint may stop the growth of cancer cells by blocking some of the enzymes needed for cell …

  • 0 views
  • 26 Mar, 2022
  • 1 location
Efficacy and Pharmacogenomics of Salvage CLAG-M Chemotherapy in Patients With Relapse/Refractory and Secondary Acute Myeloid Leukemia

This is a prospective phase II clinical study to be conducted at the Medical College of Wisconsin. After meeting the study criteria and enrollment, patients will be treated with Cladribine, Cytarabine, Mitoxantrone, G-CSF (CLAG-M) chemotherapy and followed at periodic intervals to determine the primary and secondary objectives.

colony stimulating factor
ejection fraction
cladribine
cytarabine
filgrastim
  • 60 views
  • 01 May, 2022
  • 1 location
Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation

The purpose of this Phase I, multicenter study is to evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of AG-120 in advanced hematologic malignancies that harbor an IDH1 mutation. The first portion of the study is a dose escalation phase where cohorts of patients will receive ascending oral doses of …

bone marrow procedure
hematologic malignancy
cancer
  • 6 views
  • 07 Oct, 2022
  • 12 locations
Pediatric Acute Leukemia (PedAL) Screening Trial - Developing New Therapies for Relapsed Leukemias

This study aims to use clinical and biological characteristics of acute leukemias to screen for patient eligibility for available pediatric leukemia sub-trials. Testing bone marrow and blood from patients with leukemia that has come back after treatment or is difficult to treat may provide information about the patient's leukemia that …

  • 0 views
  • 11 Oct, 2022
  • 49 locations
An Observational Study to Assess the Safety of Xospata® 40 mg Tablet When Administered in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-Like Tyrosine Kinase 3 (FLT3) Mutation

The objective of this study is to describe the observed safety profile of Xospata® 40 mg tablet when administered in patients with relapsed or refractory AML with FLT3 mutation in routine clinical practice in Korea.

  • 0 views
  • 28 Oct, 2022
  • 7 locations